• Jacob T Gutsche, Prakash A Patel, Elizabeth K Walsh, Aris Sophocles, Sy-Yeu S Chern, David B Jones, Saif Anwaruddin, Nimesh D Desai, Stuart J Weiss, and John G T Augoustides.
• Department of Anesthesiology and Critical Care.
• J. Cardiothorac. Vasc. Anesth. 2015 Apr 1;29(2):536-41.

AbstractThe first decade of clinical experience with transcatheter aortic valve replacement since 2002 saw the development of 2 main valve systems, namely the Edwards Sapien balloon-expandable valve series and the Medtronic self-expanding CoreValve. These 2 valve platforms now have achieved commercial approval and application worldwide in patients with severe aortic stenosis whose perioperative risk for surgical intervention is high or extreme. In the second decade of transcatheter aortic valve replacement, clinical experience and refinements in valve design have resulted in clinical drift towards lower patient risk cohorts. There are currently 2 major trials, PARTNER II and SURTAVI, that are both evaluating the role of transcatheter aortic valve replacement in intermediate-risk patient cohorts. The results from these landmark trials may usher in a new clinical paradigm for transcatheter aortic valve replacement in its second decade.Copyright © 2015. Published by Elsevier Inc.

19 keywords...

hide…